[Present status in the treatment of type 2 diabetes mellitus. Insulin-secreting agents].
The functional defect of the pancreatic beta cell represents one of the main therapeutic targets in type 2 diabetes mellitus. Among the currently available oral antidiabetic drugs, only hypoglycaemic sulfonylureas exhibit beta cell stimulating properties. However, their use has some limits, particularly those related to the risk of hypoglycaemia and the frequent secondary therapeutic failure. These drugs have largely contributed to the knowledge of the mechanisms of insulin secretion. Besides some galenic modifications of existing sulfonylureas and the development of new drugs of this family with original properties, like glimepiride, the research is essentially focused on drugs derived from the non sulfonylurea moiety of some sulfonylureas, particularly the meglitinide family, which will probably be available for the clinician in the near future. These drugs act however grossly by the same mechanism than sulfonylureas, even if their binding site on a protein coupled with the ATP sensitive K channel appears different. Among the other possible approaches suggested by the theoretical data concerning the mechanisms of insulin secretion, GLP-1 derivatives probably represent good candidates, if stable analogues are developed.
Blicklé
J F
JF
Service de médecine interne B, hôpital civil, hôpitaux universitaires de Strasbourg, France.
Andres
E
E
Neyrolles
N
N
Brogard
J M
JM
D000255:Adenosine Triphosphate / Q000378:metabolism; D000284:Administration, Oral; D001549:Benzamides / Q000627:therapeutic use; D001665:Binding Sites; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007003:Hypoglycemia / Q000139:chemically induced; D007004:Hypoglycemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism*; D000078790:Insulin Secretion; D007515:Islets of Langerhans / Q000187:drug effects / Q000378:metabolism; D015221:Potassium Channels / Q000187:drug effects; D011485:Protein Binding; D013453:Sulfonylurea Compounds / Q000009:adverse effects / Q000627:therapeutic use; D017211:Treatment Failure
D001549:Benzamides; D007004:Hypoglycemic Agents; D007328:Insulin; D015221:Potassium Channels; D013453:Sulfonylurea Compounds; C057619:glimepiride; D000255:Adenosine Triphosphate; C030516:meglitinide